October 6, 2020

A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics

Press release

October 2, 2020

Engineered T Cells Directed at Tumors With Defined Allelic Loss

Molecular Immunology

October 1, 2020

Engineered T Cells Directed at Tumors With Defined Allelic Loss

3rd Cell Therapies and Immunotherapy Conference

August 31,  2020

A Computational Approach to Predict Off-target Peptide Selectivity of pMHC Targeting Therapeutics

The Essential Protein Engineering & Cell Therapy Summit Virtual

August 5, 2020

Structure-function Relationships of Chimeric Antigen Receptors in Acute T Cell Responses to Antigen

Molecular Immunology

November 21, 2019

Single Variable Domains from the T Cell Receptor β Chain Function as Mono-and Bifunctional CARs and TCRs

Scientific Reports

November 5, 2019

A2 Biotherapeutics Emerges From Stealth Mode With $57M Series A to Develop a Pipeline of Selective Tumor Cell Therapeutics

Press release